|
1
|
Strumberg D, Scheulen ME, Schultheis B,
Richly H, Frost A, Büchert M, Christensen O, Jeffers M, Heinig R,
Boix O and Mross K: Regorafenib (BAY 73–4506) in advanced
colorectal cancer: A phase I study. Br J Cancer. 106:1722–1727.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mross K, Frost A, Steinbild S, Hedbom S,
Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O and
Christensen O: A phase I dose-escalation study of regorafenib (BAY
73–4506), an inhibitor of oncogenic, angiogenic, and stromal
kinases, in patients with advanced solid tumors. Clin Cancer Res.
18:2658–2667. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grothey A, Van Cutsem E, Sobrero A, Siena
S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et
al: Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): An international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sorbye H, Mauer M, Gruenberger T,
Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO,
Primrose JN, Walpole ET, et al: Predictive factors for the benefit
of perioperative FOLFOX for resectable liver metastasis in
colorectal cancer patients (EORTC Intergroup Trial 40983). Ann
Surg. 255:534–539. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schwarz L, Michel P and Scotté M:
Predictive factors for the benefit of perioperative FOLFOX for
resectable liver metastasis in colorectal cancer patients (EORTC
Intergroup Trial 40983). Ann Surg. 261:e28–e29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New Response Evaluation Criteria in Solid Tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adam R, Wicherts DA, de Haas RJ, Aloia T,
Lévi F, Paule B, Guettier C, Kunstlinger F, Delvart V, Azoulay D
and Castaing D: Complete pathologic response after preoperative
chemotherapy for colorectal liver metastases: Myth or reality? J
Clin Oncol. 26:1635–1641. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rubbia-Brandt L, Giostra E, Brezault C,
Roth AD, Andres A, Audard V, Sartoretti P, Dousset B, Majno PE,
Soubrane O, et al: Importance of histological tumor response
assessment in predicting the outcome in patients with colorectal
liver metastases treated with neo-adjuvant chemotherapy followed by
liver surgery. Ann Oncol. 18:299–304. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shindoh J, Loyer EM, Kopetz S,
Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA,
Charnsangavej C, Aloia TA and Vauthey JN: Optimal morphologic
response to preoperative chemotherapy: An alternate outcome end
point before resection of hepatic colorectal metastases. J Clin
Oncol. 30:4566–4572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chun YS, Vauthey JN, Boonsirikamchai P,
Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Kaur H,
Charnsangavej C and Loyer EM: Association of computed tomography
morphologic criteria with pathologic response and survival in
patients treated with bevacizumab for colorectal liver metastases.
JAMA. 302:2338–2344. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Matsuhashi N, Takahashi T, Tanahashi T,
Matsui S, Sasaki Y, Tanaka Y, Okumura N, Yamaguchi K, Osada S and
Yoshida K: The efficacy of ‘Abound™’, a nutritional supplement
containing L-glutamine, L-arginine, citric acid, and calcium HMB,
for skin disorders that developed as adverse drug reactions to
anti-EGFR antibody preparation administration: Pilot study. Int J
Colorectal Dis. 31:1055–1057. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Matsuhashi N, Takahashi T, Nonaka K,
Ichikawa K, Yawata K, Tanahashi T, Imai H, Sasaki Y, Tanaka Y,
Okumura N, et al: A case report on efficacy of Abound™ for
anti-EGFR antibody-associated skin disorder in metastatic colon
cancer. World J Surg Oncol. 12:352014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ronot M, Bouattour M, Wassermann J, Bruno
O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond
E and Faivre S: Alternative Response Criteria (Choi, European
Association for the Study of the Liver, and modified Response
Evaluation Criteria in Solid Tumors [RECIST]) versus RECIST 1.1 in
patients with advanced hepatocellular carcinoma treated with
sorafenib. Oncologist. 19:394–402. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Edeline J, Boucher E, Rolland Y, Vauléon
E, Pracht M, Perrin C, Le Roux C and Raoul JL: Comparison of tumor
response by Response Evaluation Criteria in Solid Tumors (RECIST)
and modified RECIST in patients treated with sorafenib for
hepatocellular carcinoma. Cancer. 118:147–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kawaoka T, Aikata H, Murakami E, Nakahara
T, Naeshiro N, Tanaka M, Honda Y, Miyaki D, Nagaoki Y, Takaki S, et
al: Evaluation of the mRECIST and α-fetoprotein ratio for
stratification of the prognosis of
advanced-hepatocellular-carcinoma patients treated with sorafenib.
Oncology. 83:192–200. 2012. View Article : Google Scholar : PubMed/NCBI
|
